journal
https://read.qxmd.com/read/37740927/frequency-and-characteristics-of-chemotherapy-associated-thrombotic-microangiopathy-analysis-from-a-large-pharmacovigilance-database
#1
LETTER
Nattawat Klomjit, Richard Evans, Thomas K Le, Sophia L Wells, Jessica Ortega, Olivia Green-Lingren, Marshall Mazepa, Meghan E Sise, Kenar D Jhaveri, Shruti Gupta
We used the information component (IC), a disproportionate Bayesian analysis comparing the number of observed versus expected adverse drug reactions, to determine the potential association between anti-neoplastic agents and thrombotic microangiopathy (TMA). The IC025 indicates the lower end of 95% of IC, in which a value >0 suggests a disproportionality signal between the drug of interest and the adverse drug reaction. Carfilzomib had the highest IC025 for TMA among all studied chemotherapies followed by gemcitabine, mitomycin, bevacizumab, and bortezomib...
September 23, 2023: American Journal of Hematology
https://read.qxmd.com/read/37740926/analysis-of-60-patients-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-and-t-cell-lymphoblastic-lymphoma-treated-with-cd7-targeted-chimeric-antigen-receptor-t-cell-therapy
#2
JOURNAL ARTICLE
Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Jianping Zhang, Yue Lu, Yan-Li Zhao, David Jin, Jianqiang Li, Peihua Lu
While the use of chimeric antigen receptor-T (CAR-T) therapy for T-cell malignancies is in the early stage of clinical trials, it exhibits substantial potential to offer long-term remission for patients with refractory/relapsed (R/R) T-cell malignancies. In our phase I/II clinical trials, 65 pediatric and adult patients with R/R T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/LBL) were enrolled (NCT04572308 and NCT04916860). Of these, 60 participants (T-ALL 35, T-LBL 25) received a single dose of naturally selected anti-CD7 CAR (NS7CAR) T cells at three levels: a low dose (5 × 105 /kg), a medium dose (1 to 1...
September 23, 2023: American Journal of Hematology
https://read.qxmd.com/read/37740922/myelokathexis-in-an-18-year-old-male-patient-with-severe-neutropenia-and-lymphopenia
#3
Endi Wang, Yue Zhao, Sophie Parks, Imran Siddiqi
No abstract text is available yet for this article.
September 23, 2023: American Journal of Hematology
https://read.qxmd.com/read/37732882/mast-cell-cytomorphology-and-treatment-outcome-in-mast-cell-leukemia
#4
LETTER
Ayalew Tefferi, Animesh Pardanani, Aref Al-Kali, Hassan Alkhateeb, Kristen McCullough, Mrinal Patnaik, William J Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M Palmer, Naseema Gangat, Katalin Kelemen, Attilio Orazi, Dong Chen, Kaaren K Reichard
No abstract text is available yet for this article.
September 21, 2023: American Journal of Hematology
https://read.qxmd.com/read/37732822/poems-syndrome-update-on-diagnosis-risk-stratification-and-management
#5
JOURNAL ARTICLE
Angela Dispenzieri
DISEASE OVERVIEW: POEMS syndrome is a life-threatening condition due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder, sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. DIAGNOSIS: The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria...
September 21, 2023: American Journal of Hematology
https://read.qxmd.com/read/37732815/successful-cord-blood-transplantation-for-del7q-myelodysplastic-syndrome-in-pearson-marrow-pancreas-syndrome
#6
LETTER
Zacharia H Belgacem, Sonia M Dubois, Elad Jacoby, Paul L Martin, Sumit B Parikh, Mark D Fleming, Suneet Agarwal
No abstract text is available yet for this article.
September 21, 2023: American Journal of Hematology
https://read.qxmd.com/read/37732813/erratum-to-checkpoint-inhibitor-based-salvage-regimens-prior-to-autologous-stem-cell-transplant-improve-event-free-survival-in-relapsed-refractory-classic-hodgkin-lymphoma
#7
(no author information available yet)
No abstract text is available yet for this article.
September 21, 2023: American Journal of Hematology
https://read.qxmd.com/read/37728241/comparison-of-the-prognostic-predictive-value-of-molecular-international-prognostic-scoring-system-and-revised-international-prognostic-scoring-system-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-for-myelodysplastic-neoplasms
#8
LETTER
Tingting Yang, Binqian Jiang, Yi Luo, Yanmin Zhao, Guifang Ouyang, Jian Yu, Jianping Lan, Ying Lu, Xiaoyu Lai, Baodong Ye, Yi Chen, Lizhen Liu, Yang Xu, Pengfei Shi, Haowen Xiao, Huixian Hu, Qunyi Guo, Huarui Fu, Yishan Ye, Xinyu Wang, Jie Sun, Weiyan Zheng, Jingsong He, Yi Zhao, Wenjun Wu, Zhen Cai, Guoqing Wei, He Huang, Jimin Shi
No abstract text is available yet for this article.
September 20, 2023: American Journal of Hematology
https://read.qxmd.com/read/37718626/bone-marrow-fibrosis-is-associated-with-non-response-to-cd19-car-t-cell-therapy-in-b-acute-lymphoblastic-leukemia
#9
JOURNAL ARTICLE
Joshua Anil, Ahab Alnemri, Andrew Lytle, Brian Lockhart, Ashley E Anil, Michael Baumgartner, Kirubel Gebre, Jared McFerran, Stephan A Grupp, Susan R Rheingold, Vinodh Pillai
CD19 directed CAR T-cell therapy is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The role of the pre-CAR bone marrow (BM) stromal microenvironment in determining response to CAR T-cell therapy has been understudied. We performed whole transcriptome analysis, reticulin fibrosis assessment and CD3 T-cell infiltration on BM core biopsies from pre- and post-CAR timepoints for 61 patients, as well as on a cohort of 54 primary B-ALL samples. Pathways of fibrosis, extracellular matrix development, and associated transcription factors AP1 and TGF-β3, were enriched and upregulated in nonresponders (NR) even prior to CAR T cell therapy...
September 18, 2023: American Journal of Hematology
https://read.qxmd.com/read/37713530/chronic-gvhd-in-a-prognostic-model-graft-versus-leukemia-predictor-or-immortal-time-bias
#10
LETTER
Erik G J von Asmuth, Arjan C Lankester, Hein Putter
No abstract text is available yet for this article.
September 15, 2023: American Journal of Hematology
https://read.qxmd.com/read/37713504/severe-cutaneous-necrosis-in-antiphospholipid-syndrome
#11
LETTER
Mariam Mostafa, Amir Mahmoud, Hebat-Allah Egiza, Chengu Niu, Mohamed Elbahnasawy, Yasmin Yusuf, Peter Kouides
No abstract text is available yet for this article.
September 15, 2023: American Journal of Hematology
https://read.qxmd.com/read/37706580/targeted-dosing-of-anti-thymocyte-globulin-in-adult-unmanipulated-haploidentical-peripheral-blood-stem-cell-transplantation-a-single-arm-phase-2-trial
#12
JOURNAL ARTICLE
Haitao Wang, Nan Wang, Lili Wang, Jishan Du, Fei Li, Yangliu Shao, Bo Peng, Songhua Luan, Lu Wang, Xiangshu Jin, Chunji Gao, Liping Dou, Daihong Liu
Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence. To investigate the optimal dosing of ATG, we established a targeted dosing strategy based on ATG concentration monitoring for haploidentical peripheral blood stem cell transplantation (haplo-PBSCT)...
September 14, 2023: American Journal of Hematology
https://read.qxmd.com/read/37705260/germline-ddx41-mutant-predisposition-syndromes-slow-driver-states-to-hematological-malignancies
#13
EDITORIAL
Timothy M Chlon, Mrinal M Patnaik
No abstract text is available yet for this article.
September 13, 2023: American Journal of Hematology
https://read.qxmd.com/read/37705256/drivers-of-deep-molecular-response-and-long-term-outcomes-in-patients-with-core-binding-factor-acute-myeloid-leukemia
#14
LETTER
Parth C Patel, Somedeb Ball, Akriti G Jain, Chen Wang, Mohammad O Hussaini, Luis E Aguirre, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E Lancet, Rami S Komrokji, David A Sallman
A swimmer plot on clinical course of patients undergoing allogeneic stem cell transplant for core binding factor acute myeloid leukemia.
September 13, 2023: American Journal of Hematology
https://read.qxmd.com/read/37698348/immunomodulatory-cytokines-and-clonal-dynamics-in-low-risk-myelodysplastic-syndromes-patients-treated-with-luspatercept
#15
LETTER
Bruno Fattizzo, Alfredo Marchetti, Anna Zaninoni, Marta Lionetti, Marta Riva, Lorenzo Rizzo, Loredana Pettine, Nicole Galli, Federico Mazzon, Elisa Fermo, Akihiro Maeda, Alessio Marella, Matteo Claudio Da Vià, Francesco Passamonti, Niccolò Bolli, Wilma Barcellini
No abstract text is available yet for this article.
September 12, 2023: American Journal of Hematology
https://read.qxmd.com/read/37688525/reappraisal-of-mast-cell-leukemia-based-on-a-single-institution-review-of-16-cases-mast-cell-morphology-determines-clinical-outcome
#16
LETTER
Animesh Pardanani, Ayalew Tefferi, Aref Al-Kali, Mrinal Patnaik, William J Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K Reichard, Dong Chen
Cytologic abnormalities of atypical mast cells in mastocytosis. The mature mast cells have oval-shaped nuclei, cytoplasmic hypogranulation and spindle-shaped cytology. or well-differentiated displaying a round nucleus with condensed chromatin, and abundant dense cytoplasmic granulations. Immature mast cells include promastocytes and metachromatic blast-like forms.
September 9, 2023: American Journal of Hematology
https://read.qxmd.com/read/37688521/prospective-analysis-to-determine-barriers-to-allogeneic-hematopoietic-cell-transplantation-in-patients-with-acute-leukemia
#17
JOURNAL ARTICLE
Karthik Nath, Jasme Lee, Theresa A Elko, Lauren Levy, Elaina Preston, Sean M Devlin, Doris M Ponce, Richard J Lin, Brian C Shaffer, Christina Cho, Ioannis Politikos, Ann A Jakubowski, Jae H Park, Raajit Rampal, Miguel-Angel Perales, Martin S Tallman, Juliet N Barker, Ellin Berman, Roni Tamari, Eytan Stein, Sergio A Giralt, Boglarka Gyurkocza
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate and eligible for HCT did not subsequently undergo transplant. Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy...
September 9, 2023: American Journal of Hematology
https://read.qxmd.com/read/37688507/effects-of-2-3-dpg-knockout-on-scd-phenotype-in-townes-scd-model-mice
#18
JOURNAL ARTICLE
Amey Barakat, Reema Jasuja, Lindsay Tomlinson, Zane Wenzel, Lila Ramaiah, Betty A Petterson, Brendon Kapinos, Anagha Sawant, Vicente Pagan, Nathanael Lintner, Denise Field, Youngwook Ahn, Kelly M Knee
Sickle cell disease (SCD) is a severe, multisystemic hematological disorder that impacts nearly every major organ in adults. The current approved treatments for SCD directly target mutant hemoglobin or address downstream disease pathology. Several compounds targeting reduction of 2,3-DPG by activation of Pyruvate Kinase-R are currently being evaluated in SCD patients. In this study, we genetically engineered a mouse lacking 2,3-DPG on the Townes SCD mouse model background and evaluated the effects of 2,3-DPG loss on disease pathology...
September 9, 2023: American Journal of Hematology
https://read.qxmd.com/read/37683111/acute-myeloid-leukemia-with-mutated-tp53-is-this-newly-proposed-entity-oversimplifying-a-complex-group-of%C3%A2-neoplasms
#19
LETTER
Hong Fang, L Jeffery Medeiros, Wei Wang
No abstract text is available yet for this article.
September 8, 2023: American Journal of Hematology
https://read.qxmd.com/read/37671681/a-novel-missense-variant-in-atp11c-is-associated-with-reduced-red-blood-cell-phosphatidylserine-flippase-activity-and-mild-hereditary-hemolytic-anemia
#20
JOURNAL ARTICLE
Myrthe J van Dijk, Brigitte A van Oirschot, Alexander N Harrison, Steffen M Recktenwald, Min Qiao, Amaury Stommen, Anne-Sophie Cloos, Juliette Vanderroost, Romano Terrasi, Kuntal Dey, Jennifer Bos, Minke A E Rab, Anna Bogdanova, Giampaolo Minetti, Giulio G Muccioli, Donatienne Tyteca, Stéphane Egée, Lars Kaestner, Robert S Molday, Eduard J van Beers, Richard van Wijk
Adenosine Triphosphatase (ATPase) Phospholipid Transporting 11C gene (ATP11C) encodes the major phosphatidylserine (PS) flippase in human red blood cells (RBCs). Flippases actively transport phospholipids (e.g., PS) from the outer to the inner leaflet to establish and maintain phospholipid asymmetry of the lipid bilayer of cell membranes. This asymmetry is crucial for survival since externalized PS triggers phagocytosis by splenic macrophages. Here we report on pathophysiological consequences of decreased flippase activity, prompted by a patient with hemolytic anemia and hemizygosity for a novel c...
September 6, 2023: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.